Filing Flows › BeOne Medicines (ONC) › Guidance & outlook

BeOne Medicines (ONC) guidance and outlook

BeOne Medicines (ONC) raised its guidance on Nov 5, 2026: Revenue $6.9B–$7.0B for FY2026; Gross margin 80% for FY2026; Gross margin 80% for FY2026; Other income $25.0M–$50.0M for FY2026. BeOne Medicines' 10-Q filed Nov 5, 2026 makes 13 forward-looking statements.

Guidance and outlook

Latest guidance

From the earnings release filed Nov 5, 2026 (8-K on EDGAR).

Forward-looking statements, 10-Q filed Nov 5, 2026

• The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of our historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information.
• On August 18, 2026, we announced the renewal of our partnership with the BeOne Care Foundation and The Max Foundation through 2028 to expand access to BRUKINSA ® (zanubrutinib) for the treatment of chronic lymphocytic leukemia in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively.
• The income tax expense for the three months ended September 30, 2026 and 2025 was primarily attributable to the application of our expected current worldwide effective tax rate for the full year to year-to-date actual pre-tax income, reflecting the mix of taxable income across jurisdictions as well as the impact of certain discrete items.
• Given the Company’s recent history of earnings, management believes that there is a reasonable possibility that, within the next twelve months, sufficient positive evidence may become available to allow management to reach a conclusion that a significant portion of the valuation allowance recorded against the deferred tax assets held will be reversed.
• The ongoing tax audits in various jurisdictions could impact future tax expense if tax authorities in their administration of tax laws during open audits may lead us to change our assessment of whether or not it is more likely than not that certain tax benefit positions will be sustained.
• The income tax expense for the nine months ended September 30, 2026 and 2025 was primarily attributable to the application of our expected current worldwide effective tax rate for the full year to year-to-date actual pre-tax income, reflecting the mix of taxable income across jurisdictions as well as the impact of certain discrete items.
• Based on our current operating plan, we expect that our operating cash flows and existing cash and cash equivalents as of September 30, 2026 will enable us to fund our operating expenses and planned long-term investments for at least the next 12 months after the date that the financial statements included in this report are issued.
• We believe we will have sufficient cash and cash equivalents and other sources of capital to be able to repay and/or refinance those debt obligations on a consolidated basis as they become due principally in 2027 and 2028.
• Our classification of the liability between current and non-current is based on our expectations of royalty revenue from Amgen over the next 12 months, which will be paid to Royalty Pharma in accordance with the terms of the Royalty Agreement.
• We expect to repay approximately $258.8 million of outstanding bank loans in the next 12 months.
• We plan to fund our material cash requirements with cash on hand.
• While we have classified the upfront payment and the option exercise payment received from Royalty Pharma as a liability, the repayment of this obligation to Royalty Pharma will be made upon the receipt of royalties from Amgen throughout the royalty period, which is anticipated to extend at least through 2041.

BeOne Medicines' latest quarter

Questions

Did BeOne Medicines raise or lower its guidance?

BeOne Medicines (ONC) raised its guidance on Nov 5, 2026: Revenue $6.9B–$7.0B for FY2026; Gross margin 80% for FY2026; Gross margin 80% for FY2026; Other income $25.0M–$50.0M for FY2026.

What does BeOne Medicines expect?

The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of our historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. On August 18, 2026, we announced the renewal of our partnership with the BeOne Care Foundation and The Max Foundation through 2028 to expand access to BRUKINSA ® (zanubrutinib) for the treatment of chronic lymphocytic leukemia in low- and middle-income countries, with the program projected to support approximately 1,000 patients c

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.